Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

PHASE4RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Hemophilia A
Interventions
DRUG

Nuwiq

Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).

Trial Locations (13)

78229

RECRUITING

UT Health San Antonio, San Antonio

Unknown

RECRUITING

Helsinki University Hospital,Coagulation Disorder Unit, Helsinki

RECRUITING

Avenue de la République, Chambray-lès-Tours

RECRUITING

CHU de Nantes Hôtel-Dieu, Nantes

RECRUITING

Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin, Bonn

RECRUITING

Gerinnungszentrum Rhein-Ruhr, Duisburg

RECRUITING

Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik, Hamburg

RECRUITING

"Aziendo Ospedaliera Puglieze Ciaccio", Catanzaro

RECRUITING

"Policlinico P. Giaconne", Palermo

RECRUITING

Clinical Center for Serbia, Belgrade

RECRUITING

Hospital Universitario la Paz, Madrid

RECRUITING

Hospital Universitario Virgen del Rocio, Seville

NOT_YET_RECRUITING

St. James's University Hospital, Leeds

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY